Repurposing existing drugs for cancer treatment has emerged as one of oncology's most pragmatic frontiers — bypassing decades of safety testing by leveraging compounds already cleared for human use. A decades-old antiparasitic drug now shows mechanistic promise against breast cancer by dismantling a molecular survival circuit that tumors rely on to resist chemotherapy.
Niclosamide, long used to treat tapeworm infections, was found to suppress breast cancer progression through a previously undercharacterized signaling axis: ATP6AP1–YY1–XIAP. ATP6AP1 is an accessory subunit of the vacuolar ATPase proton pump, whose overexpression appears to stabilize YY1, a transcription factor that in turn drives expression of XIAP — an inhibitor of apoptosis protein that shields cancer cells from programmed cell death. By disrupting this cascade, niclosamide effectively stripped tumor cells of a key anti-apoptotic defense. Critically, when combined with paclitaxel, a standard first-line chemotherapy agent, niclosamide significantly enhanced tumor cell killing compared to either agent alone, suggesting a synergistic mechanism rooted in restored apoptotic sensitivity.
This finding adds to a growing body of evidence implicating niclosamide as a broad oncological candidate — prior work has linked it to Wnt/β-catenin and STAT3 pathway inhibition across multiple cancer types. What distinguishes this study is its delineation of a novel molecular axis rather than confirmation of already-established targets. That specificity matters: it opens concrete drug-design opportunities and helps explain why some breast cancer subtypes might respond preferentially. However, significant caveats apply. Research at this stage is almost certainly preclinical — cell-line and possibly animal-model data — meaning clinical translation remains distant and uncertain. XIAP inhibition as a therapeutic strategy has faced prior challenges in human trials due to compensatory resistance mechanisms. Whether the ATP6AP1–YY1 link holds in patient-derived tumors, and at what niclosamide concentrations, will be the decisive questions. This is an intriguing mechanistic advance, but firmly incremental rather than practice-changing.